Cargando…
Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2
BACKGROUND: Booster doses for COVID-19 vaccinations are currently recommended and approved in many countries. However, we need more evidence on the immune response of individuals to booster doses of inactivated vaccines and the neutralizing effect against the variants of concerns of SARS-CoV-2. OBJE...
Autores principales: | Mahmoud, Sally, Ganesan, Subhashini, Al kaabi, Nawal, Naik, Shivaraj, Elavalli, Santosh, Gopinath, Prem, Ali, Alaa Mousa, Bazzi, Lara, Warren, katherine, Zaher, Walid Abbas, Hosani, Farida Al |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005219/ https://www.ncbi.nlm.nih.gov/pubmed/35439702 http://dx.doi.org/10.1016/j.jcv.2022.105161 |
Ejemplares similares
-
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
por: Al Kaabi, Nawal, et al.
Publicado: (2022) -
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates
por: Al Kaabi, Nawal, et al.
Publicado: (2022) -
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022) -
Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)
por: Ismail AlHosani, Farida, et al.
Publicado: (2022) -
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022)